COVID-19

News

AZ says second COVID jab dose isn't linked to rare clot reac...

A new analysis has suggested that the rare blood clot side effects linked to AstraZeneca's COVID-19 vaccine Vaxzevria don't occur after a second dose.

News

First published data backs CanSino's inhaled COVID vaccine

Early-stage clinical data with CanSino Biologics' inhaled COVID-19 vaccine show that it was able to stimulate neutralising antibodies against SARS-CoV-2 at a dose well below that required w

Views & Analysis

COVID-19: We don’t need another hero

We’ve all got used to hailing healthcare staff as heroes over the past year. Of course they deserve every ounce of admiration, even though many are uncomfortable with the adulation.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer takes alteplase to phase 3 for COVID, but drops a...

Boehringer Ingelheim's latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme

News

Rapid COVID immune status test launched in UK, Ireland

You've had your two COVID-19 jabs, but are you actually protected against infection?

News

Resourceful or risky-The UKs controversial COVID-19 vaccine strategy

Study finds jabs cut severe variant COVID disease after one ...

A real-world study carried out in Canada has found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce the chances of being hospitalised or dying from variants of co

AZ says second COVID jab dose isn't linked to rare clot reac...

First published data backs CanSino's inhaled COVID vaccine

COVID-19: We don’t need another hero

Boehringer takes alteplase to phase 3 for COVID, but drops a...

Rapid COVID immune status test launched in UK, Ireland

Study finds jabs cut severe variant COVID disease after one ...

Recordati gets €10.9bn takeover bid from private equity firm

Using AI-driven synthetic personas to take your insights fur...

COVID-19

Editor's Picks